scispace - formally typeset
W

Wen Jin Wu

Researcher at Center for Drug Evaluation and Research

Publications -  33
Citations -  1074

Wen Jin Wu is an academic researcher from Center for Drug Evaluation and Research. The author has contributed to research in topics: Trastuzumab & Cardiotoxicity. The author has an hindex of 14, co-authored 33 publications receiving 838 citations.

Papers
More filters
Journal ArticleDOI

Cdc42 Regulates E-cadherin Ubiquitination and Degradation through an Epidermal Growth Factor Receptor to Src-mediated Pathway

TL;DR: It is reported that Ca2+ depletion induces E-cadherin ubiquitination and lysosomal degradation and that Cdc42 plays an important role in regulating this process, and it is found that GTP-dependent binding of CDC42 to E- cadher in is critical for C dc42 to induce the dissolution of adherens junctions.
Journal ArticleDOI

Trastuzumab Alters the Expression of Genes Essential for Cardiac Function and Induces Ultrastructural Changes of Cardiomyocytes in Mice

TL;DR: It is reported that trastuzumab significantly alters the expression of myocardial genes essential for DNA repair, cardiac and mitochondrial functions, which is associated with impaired left ventricular performance in mice coupled with significant ultrastructural alterations in cardiomyocytes revealed by electron microscopy.
Journal ArticleDOI

Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of Cdc42.

TL;DR: It is shown that Cdc42 and c-Cbl are critical components involved in the regulation of EGFR protein levels and that restoration of proper EGFR degradation by disrupting CDC42 regulation of c- Cbl can reduce cell proliferation and migration in MDA-MB-231 and BT20 cells.
Journal ArticleDOI

Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers.

TL;DR: The novel role of DNA topoisomerase IIB as a shared target for enhanced cardiotoxicity induced by trastuzumab and anthracyclines-based combination regimens is discussed, and the potential impact of trastzumab intervention in immune checkpoint inhibitors-based therapies is speculated.
Journal ArticleDOI

Trastuzumab cardiotoxicity: from clinical trials to experimental studies.

TL;DR: A comprehensive overview of the current knowledge on the cardiotoxicity of trastuzumab is given, primarily focusing on data from clinical trials and highlighting the main molecular mechanisms proposed.